Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort

Background: Breast cancers expressing low (1-9%) immunohistochemistry levels of estrogen and progesterone hormone receptors (HR), remain an uncertain category, being considered either as triple negative (TN) breast cancers or HR-positive (HR+) tumors across guidelines or approvals. Methods: ESME is...

Полное описание

Библиографические подробности

Главные авторы:	Marie Alexandre, Eva Teruel, Florence Dalenc, Thibaut de la Motte Rouge, Etienne Brain, Vincent Massard, Monica Arnedos, Audrey Mailliez, Jean-Marc Ferrero, Thomas Bachelot, Isabelle Desmoulins, Marie-Ange Mouret-Reynier, Christelle Levy, Antony Gonçalves, Anca Berghian, Thierry Petit, Jean-Sébastien Frenel, Anne-Laure Martin, Thomas Grinda, William Jacot
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-08-01
Серии:	Breast
Предметы:	Metastatic breast cancer Hormone receptor low Real-world data Overall survival
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S0960977626001256
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!